NCT00931372View on ClinicalTrials.gov

Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Lixisenatide (AVE0010)

Solution for subcutaneous injection 100 µg/mL

DRUG

Placebo

Subcutaneous injection

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Profil GmbH, Neuss, Germany

UNKNOWN

lead

Sanofi

INDUSTRY